SEC Comment Letter 0000000000-24-003330 to Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc.
Date: March 27, 2024 · CIK: 0001327273 · Accession: 0000000000-24-003330
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278163
Letter
United States securities and exchange commission logo March 27, 2024 Maria Palasis Chief Executive Officer Lyra Therapeutics, Inc. 480 Arsenal Way Watertown, MA 02472 Re:Lyra Therapeutics, Inc. Registration Statement on Form S-3 Filed March 22, 2024 File No. 333-278163 Dear Maria Palasis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Wesley C. Holmes
Show Raw Text
United States securities and exchange commission logo
March 27, 2024
Maria Palasis
Chief Executive Officer
Lyra Therapeutics, Inc.
480 Arsenal Way
Watertown, MA 02472
Re:Lyra Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 22, 2024
File No. 333-278163
Dear Maria Palasis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Wesley C. Holmes